Reference
- Anada Y, Igarashi Y, Kihara A. (2007). The immunomodulator FTY720 is phosphorylated and released from platelets. Eur J Pharmacol 568:106–11
- Brinkmann V, Davis MD, Heise CE, et al. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–7
- Collard F, Delpierre G, Stroobant V, et al. (2003). A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 52:2888–95
- Conner JR, Benjamin B, Szwergold BS. (2004). The expression of the genes for fructosamine-3-kinase and fructosamine-3-kinase-related protein appears to be constitutive and unaffected by environmental signals. Biochem Biophys Res Commun 323:932–6
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Delpierre G, Vanstapel F, Stroobant V, Schaftingen EV. (2000). Conversion of a synthetic fructosamine into its 3-phospho derivative in human erythrocytes. Biochem J 352:835–9
- Delplanque J, Delpierre G, Opperdoes FR, Schaftingen EV. (2004). Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. J Biol Chem 279:46606–13
- Freeman S, Gardiner JM. (1996). Acyclic nucleosides as antiviral compounds. Mol Biotechnol 5:125–37
- Hellwig A, Scherber A, Koehler C, et al. (2014). A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes. Clin Chem Lab Med 52:93–101
- Inaba S, Ikeda T, Goto M, et al. (2015). Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys. Xenobiotica 45:1063–80
- Kapoor M, Siegel RA. (2013). Prodrug/enzyme based acceleration of absorption of hydrophobic drugs: an in vitro study. Mol Pharm 10:3519–24
- Mechtcheriakova D, Wlachos A, Sobanov J, et al. (2007). FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett 581:3063–8
- Moberly JB, Rohatagi S, Zahir H, et al. (2012a). Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator. J Clin Pharmacol 52:996–1006
- Moberly JB, Ford DM, Zahir H, et al. (2012b). Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. J Neuroim 246:100–7
- Nishi T, Miyazaki S, Takemoto T, et al. (2011). Discovery of CS-0777: a potent, selective, and orally active S1P1 Agonist. ACS Med Chem Lett 2:368–72
- Paugh SW, Payne SG, Barbour SE, et al. (2003). The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189–93
- Sakurai H, Kubota K, Inaba S, et al. (2013). Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling. Mol Cell Proteomics 12:2313–23
- Szwergold BS, Howell S, Beisswenger PJ. (2001). Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50:2139–47
- Szwergold BS, Bunker RD, Loomes KM. (2011). The physiological substrates of fructosamine-3-kinase-related-protein (FN3KRP) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products). Med Hypotheses 77:739–44
- Van Hoo VO, De Broe ME. (1994). Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 31:197–293
- Yonesu K, Kubota K, Tamura M, et al. (2011). Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes. J Biol Chem 286:24765–75